Kensey Nash Corp. (KNSY, Financial) filed Annual Report for the period ended 2010-06-30.
Kensey Nash Corp. has a market cap of $252.4 million; its shares were traded at around $26.74 with a P/E ratio of 14.3 and P/S ratio of 3.1. Kensey Nash Corp. had an annual average earning growth of 8.3% over the past 10 years.KNSY is in the portfolios of Chuck Royce of Royce& Associates, Jim Simons of Renaissance Technologies LLC.
In June 2005, we entered into an Angio-Seal component supply agreement with St. Jude Medical that expires in December 2010. Under this supply agreement, we are the exclusive supplier of the collagen plug component of the Angio-Seal device, as well as a 30% supplier of the anchor component. In June 2010, we entered into a new two-year supply agreement for the period from January 1, 2011 to December 31, 2012. The new supply agreement provides for us to be the exclusive outside supplier of collagen plugs, one of the key resorbable components of the Angio-Seal device. The new supply agreement provides for calendar year 2011 minimum order levels equivalent to approximately 25% of our fiscal year 2010 collagen plug sales and calendar year 2012 minimum order levels equivalent to approximately 20% of our fiscal year 2010 collagen plug sales. The new supply agreement does not call for us to supply any polymer anchors. In fiscal year 2010, collagen plug sales to St. Jude Medical were approximately $17.1 million and polymer anchor sales were approximately $1.9 million. Under the new supply agreement, if St. Jude Medical only purchases the minimum levels of collagen plugs, our related product sales will be substantially lower than under the agreement that expires at the end of calendar year 2010. Royalties under the Angio-Seal license agreement between our Company and St. Jude Medical, which are based on total net end-user sales of the Angio-Seal device, are not affected by this new supply agreement.
Read the The complete Report
Kensey Nash Corp. has a market cap of $252.4 million; its shares were traded at around $26.74 with a P/E ratio of 14.3 and P/S ratio of 3.1. Kensey Nash Corp. had an annual average earning growth of 8.3% over the past 10 years.KNSY is in the portfolios of Chuck Royce of Royce& Associates, Jim Simons of Renaissance Technologies LLC.
Highlight of Business Operations:
The aggregate market value of the registrants Common Stock held by non-affiliates of the registrant as of December 31, 2009 (the last business day of the registrants most recently completed second fiscal quarter) was $187,167,374, based on the closing price per share of Common Stock of $25.50 as of such date reported by the NASDAQ Global Select Market. Shares of the registrants Common Stock held by each executive officer and director and by each person who owns 10% or more of the outstanding Common Stock have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.In June 2005, we entered into an Angio-Seal component supply agreement with St. Jude Medical that expires in December 2010. Under this supply agreement, we are the exclusive supplier of the collagen plug component of the Angio-Seal device, as well as a 30% supplier of the anchor component. In June 2010, we entered into a new two-year supply agreement for the period from January 1, 2011 to December 31, 2012. The new supply agreement provides for us to be the exclusive outside supplier of collagen plugs, one of the key resorbable components of the Angio-Seal device. The new supply agreement provides for calendar year 2011 minimum order levels equivalent to approximately 25% of our fiscal year 2010 collagen plug sales and calendar year 2012 minimum order levels equivalent to approximately 20% of our fiscal year 2010 collagen plug sales. The new supply agreement does not call for us to supply any polymer anchors. In fiscal year 2010, collagen plug sales to St. Jude Medical were approximately $17.1 million and polymer anchor sales were approximately $1.9 million. Under the new supply agreement, if St. Jude Medical only purchases the minimum levels of collagen plugs, our related product sales will be substantially lower than under the agreement that expires at the end of calendar year 2010. Royalties under the Angio-Seal license agreement between our Company and St. Jude Medical, which are based on total net end-user sales of the Angio-Seal device, are not affected by this new supply agreement.
Read the The complete Report
